ZYBERNO
Stock Report
Updated Sep 1, 2026

Quantum BioPharma Ltd. (QNTM)

Healthcare • NASDAQ

$3.17

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
9.0/100
POOR BUSINESS
Quantum BioPharma Ltd. (QNTM) scores 9/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-534.4%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.00x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-359.0%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

Quantum BioPharma Ltd. (QNTM) stock report — Zyberno Score 9/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:3.17
Market Cap:$25.62M

Valuation Multiples (3)

P/B Ratio:5.02x
P/S Ratio:139.99x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$23.72M

Price Action & Momentum (3)

Momentum Percentile:1 / 100
% of 52-Week High:11.1%
B. Profitability Assessment

Return Metrics (5)

ROA:-244.3%
Reinvestment Rate:4.8%
Fundamental Growth Rate (g):-17.1%

Margin Analysis (1)

Ebitda Margin:-8,062.5%

Yield Metrics (2)

Earnings Yield:-$999.00
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:1.07x
Quick Ratio:1.06x
Cash Ratio:0.31x

Leverage Analysis (3)

Debt To Equity Ttm:0.00x
Debt-to-Equity Ratio:0.00x
Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-51.49x
Times Interest Earned:-51.49

Capital Structure (4)

Working Capital:420,059.00
Cash And Cash Equivalents:1,905,357.00
Long Term Debt:$0.00
Net Debt:-$1.91M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$183.03K
Cost Of Revenue Ttm:$1.39M

Profitability Breakdown (2)

-$1.21M-$15.30M

Bottom Line Performance (3)

-$27.27M
Income Before Tax:$0.00
Ebitda Ttm:-14,756,594.00

Operating Expenses (5)

Operating Expenses:0.00
R And D Expense:0.00
Sga Expense:0.00
Income Tax Expense:$0.00
Interest Expense:297,193.00

Expense Ratios (3)

R And D To Revenue Percentage:0.0%
Sga To Revenue Percentage:0.0%
Ebitda Margin:-8,062.5%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$11.16M
Current Assets:$6.48M
Ppe Net:67,029.00
Goodwill:0.00
Intangible Assets:$4.51M

Liability Structure (4)

Total Liabilities:6,058,294.00
Current Liabilities:6,058,294.00
Long Term Debt:$0.00
Short Term Debt:$0.00

Equity & Capital (3)

Equity:$5.10M
Retained Earnings:$0.00
Common Stock:0.00

Working Capital Items (3)

Accounts Receivable:1,473,655.59
Inventory:52,133.00
Accounts Payable:1,981,851.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:0.00
C. Cash Flow Analysis

Operating Activities (2)

-$8.24M-$8.24M

Investment Activities (1)

Investing Cash Flow:-$1.35M

Financing Activities (3)

Financing Cash Flow:$3.13M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (1)

Earnings Per Share Ttm:-$3.37

Revenue & Cash Per Share (2)

Sales Per Share Ttm:0.02
Operating Cash Flow Per Share:-$1.02

Book Value & Capital (2)

Book Value Per Share:$0.63
Cash Per Share:0.24

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.02x
Working Capital Turnover Ttm:0.44x

Receivables Management (2)

Receivables Turnover Ttm:0.12x
Days Sales Outstanding Ttm:2,938.83

Inventory Management (2)

Inventory Turnover Ttm:26.75x
Days Inventory Outstanding Ttm:13.64

Payables & Cash Cycle (2)

Days Payable Outstanding:518.67
Cash Conversion Cycle:2,433.80
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:80.00
Quality Score:35.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:4.8%
Fundamental Growth Rate (g):-17.1%
B. Log-Linear Regression Growth Analysis
C. Company Profile & Context

Corporate Information (6)

Symbol:QNTM
Company Name:Quantum BioPharma Ltd.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:low
Volume Category:N/A

Share Structure (3)

Shares Outstanding:8.08M
Shares Outstanding Basic:0
Shares Outstanding Diluted:0

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-09-01 10:15:11 UTC
Data Timestamp:2026-08-21T01:08:24.548875
Scroll to Top